CG Oncology (CG Oncology) Preferred Dividends : $5.94 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. CG Oncology's preferred dividends for the three months ended in Mar. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $5.94 Mil.

CG Oncology Preferred Dividends Historical Data

The historical data trend for CG Oncology's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Preferred Dividends Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Preferred Dividends

5.54

8.35

19.19

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Preferred Dividends	Get a 7-Day Free Trial			3.77	3.73	-	5.94	-

CG Oncology Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

CG Oncology (NAS:CGON) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.94 Mil.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024